Edgewise Therapeutics Management
Management criteria checks 4/4
Edgewise Therapeutics' CEO is Kevin Koch, appointed in Aug 2017, has a tenure of 7.25 years. total yearly compensation is $3.98M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $11.38M. The average tenure of the management team and the board of directors is 4.2 years and 4.8 years respectively.
Key information
Kevin Koch
Chief executive officer
US$4.0m
Total compensation
| CEO salary percentage | 15.0% |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.2yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26
Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
Sep 19We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Aug 05Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23Edgewise Therapeutics names new chief medical officer
Apr 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$116m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$4m | US$595k | -US$100m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$76m |
| Dec 31 2022 | US$5m | US$572k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$61m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$5m | US$525k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$36m |
| Jun 30 2021 | n/a | n/a | -US$27m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$2m | US$425k | -US$17m |
| Dec 31 2019 | US$741k | US$425k | -US$10m |
Compensation vs Market: Kevin's total compensation ($USD3.98M) is below average for companies of similar size in the US market ($USD6.56M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Koch (64 yo)
7.3yrs
Tenure
US$3,975,855
Compensation
Dr. Kevin Koch, Ph.D. is a Venture Partner at OrbiMed Advisors, LLC. He has been a Member of Scientific Advisory Board at OnKure, Inc. Dr. Koch serves as a Member of Scientific Advisory Board at Frontier M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 7.5yrs | US$226.00k | 0% $ 0 | |
| President | 7.3yrs | US$3.98m | 0.37% $ 11.4m | |
| Co-Founder & Independent Director | 7.5yrs | US$193.00k | 0.021% $ 638.1k | |
| Chief Business Officer | 4.2yrs | US$1.76m | 0.016% $ 486.9k | |
| Chief Medical Officer | 3.6yrs | US$1.72m | 0.015% $ 468.0k | |
| Co-Founder | 7.4yrs | US$2.46m | 0.013% $ 409.5k | |
| Chief Financial Officer | 4.2yrs | US$772.02k | 0.081% $ 2.5m | |
| General Counsel | 4.2yrs | no data | 0.0034% $ 104.6k | |
| Chief Development Officer | 1.9yrs | no data | no data |
4.2yrs
Average Tenure
64yo
Average Age
Experienced Management: EWTX's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 7.5yrs | US$226.00k | 0% $ 0 | |
| President | 7.4yrs | US$3.98m | 0.37% $ 11.4m | |
| Co-Founder & Independent Director | 3.8yrs | US$193.00k | 0.021% $ 638.1k | |
| Co-Founder | 7.3yrs | US$2.46m | 0.013% $ 409.5k | |
| Independent Director | 5.3yrs | US$199.50k | 0.017% $ 503.1k | |
| Independent Director | 3.9yrs | US$208.00k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | US$485.00k | 0.011% $ 349.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | 4.8yrs | no data | no data |
4.8yrs
Average Tenure
64yo
Average Age
Experienced Board: EWTX's board of directors are considered experienced (4.8 years average tenure).